SUCCINIC ACID PREPARATIONS IN THE COMBINATION TREATMENT OF PATIENTS WITH TUBERCULOSIS

A simple prospective investigation studied the efficacy of reamberine used to prevent antituberculosis drug-induced hepatitis in 144 patients with new-onset infiltrative pulmonary tuberculosis who were divided into 2 groups: 1) those who received a 1-2-week reamberine cycle (a study group) and 2) those who did not (a comparison group). In the study group, arrest of the symptoms of intoxication (by the leukocyte index by 35.3%) occurred in a shorter periods; drug-induced hepatitides, whose course was more favorable, were noted to develop less commonly (16.6 versus 36%). In the study group, therapeutic effectiveness was higher than that in the comparison group in terms of both the decay cavity closure index (by 30.2%) and the bacterial cessation index (by 24.8%), including in patients with multidrug-resistant in the pathogen, decay cavities were closed 13.9% more frequently and bacterial excretion cessation was seen 27.8% more often; transformation to fibrocavernous tuberculosis was also observed less commonly. The findings allow one to recommend the use of reamberine as an agent for the prevention of hepatitis caused by the intake of antituberculosis drugs during patients’ adaptation to chemotherapy (1-2weeks of treatment)

USE OF UMMUNE REPARATIVE AGENT IN THE INTEGRAL TREATMENT OF DESTRUCTIVE INFILTRATE TUBERCULOSIS

Simple prospective study was conducted in order to evaluate the e¾ciency of using the immune reparative agent of deoxyribo sodium nucleinate (derinat) in the integral treatment of 108 new patients su|ering from destructive infiltrate pulmonary tuberculosis, which were divided into two groups: the main group (MG) included 36 patients to whom derinat was prescribed (intramuscular 5 ml 0f 1.5% solution, 10 injections and inhalations through the nebuliser of the solution of derinat with saline soluion in 1:1 proportion, 2 ml of derinat solution and 2 ml o saline solution once a day, course of 20-30 procedures), the comparison group (CG) included 72 patients to whom no derinat was prescribed. The cavity closure was registered by 38.3% more often in the main group compared to the CG where patients had high risk of transformation into fibrous cavernous tuberculosis (OR = 1.222 ± 0.179). The duration of hospital stay in patients treated with derinat was 23 days shorter

DRUG-INDUCED LIVER LESIONS AND THEIR MANAGEMENT IN THE MANIFESTATIONS OF TUBERCULOSIS

The e`ciency of medication of remaxol for the management of liver lesions induced by anti-tuberculosis drugs was studied in 177 respiratory tuberculosis patients, divided into 3 groups: 1st group included 68 patients with no history of viral hepatitis and HIV infection; 2nd group included 52 patients with tuberculosis and HIV co-infection (patients from the 1st and 2nd groups received 10 day treatment with remaxol in case of drug-induced liver lesions) and 3rd control group included 57 patients (who received adamethioninum – heptor for management of the drug-induced liver lesions). 4.4% of patients from the 1st group, 7.6% from the 2nd group and 5.3% of control group manifested the improvement of the functional liver tests by the 18-20th days of the follow-up. In case of expressed concurrent conditions (viral hepatitis, diabetes etc.) and low improvement of aminotransferase level the duration of treatment of remaxol was extended up to 15 injections. Given the obtained results remaxol can be recommended for treatment of drug-induced liver lesions caused by the intake of anti-tuberculosis drugs. Tuberculosis patients with concurrent chronic alcohol addiction, HIV-infection, decompensated diabetes with low improvement of functional liver tests can be recommended to have longer treatment courses with remaxol: 15 infusions and more